A 15-year follow-up study on long-term adherence to health behaviour recommendations in women diagnosed with breast cancer

- Tollosa, Daniel N., Holliday, Elizabeth, Hure, Alexis, Tavener, Meredith, James, Erica L.

Treatment-induced symptoms, depression and age as predictors of sexual problem in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

- Ribi, Karin, Luo, Weixiu, Walley, Barbara A., Burstein, Harold J., Chirgwin, Jacquie, Ansari, Rafat H., Salim, Muhammed, van der Westhuizen, Andre, Abdi, Ehtesham, Francis, Prudence A., Chia, Stephen, Harvey, Vernon J., Giobbie-Hurder, Anita, Fleming, Gini F., Pagani, Olivia, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S.

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy

- Ribi, Karin, Luo, Weixiu, Chia, Stephen, Harvey, Vernon J., Giobbie-Hurder, Anita, Fleming, Gini F., Pagani, Olivia, Di Leo, Angelo, Colleoni, Marco, Gelber, Richard D., Goldhirsch, Aron, Coates, Alan S., Walley, Barbara A., Regan, Meredith M., Bernhard, Jürg, Burstein, Harold J., Chirgwin, Jacquie, Ansari, Rafat H., Salim, Muhammed, van der Westhuizen, Andre, Abdi, Ehtesham, Francis, Prudence A.

Dose intensity in anthracycline-based chemotherapy for metastatic breast cancer: mature results of the randomised clinical trial ANZ 9311

- Ackland, Stephen P., Gebski, V., Forbes, J. F., Coates, A. S., Zdenkowski, N., Wilson, A., Green, M., Tees, S., Dhillon, H., Van Hazel, G., Levi, J., Simes, R. J.

The intron 3 16 bp duplication polymorphism of p53 (rs17878362) is not associated with increased risk of developing triple-negative breast cancer

- Morten, Brianna C., Chiu, Simon, Oldmeadow, Christopher, Lubinski, Jan, Scott, Rodney J., Avery-Kiejda, Kelly A.

Combination breast cancer chemotherapy with doxorubicin and cyclophosphamide damages bone and bone marrow in a female rat model

- Fan, Chiaming, Georgiou, Kristen R., Morris, Howard A., McKinnon, Ross A., Keefe, Dorothy M. K., Howe, Peter R., Xian, Cory J.

Functional importance of PP2A regulatory subunit loss in breast cancer

- Watt, Lauren F., Panicker, Nikita, Mannan, Abdul, Copeland, Ben, Kahl, Richard G. S., Dun, Matthew D., Young, Barbara, Roselli, Severine, Verrills, Nicole M.

Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes

- Purrington, Kristen S., Visscher, Daniel W., Kotoula, Vassiliki, Fountzilas, George, Kabisch, Maria, Rüdiger, Thomas, Heikkilä, Päivi, Blomqvist, Carl, Cross, Simon S., Southey, Melissa C., Olson, Janet E., Gilbert, Judy, Wang, Chen, Scott, Rodney, Yannoukakos, Drakoulis, Hamann, Ute, Nevanlinna, Heli, Cox, Angela, Giles, Graham G., Eckel-Passow, Jeanette E., Lakis, Sotiris

Reevaluation of RINT1 as a breast cancer predisposition gene

- Li, Na, Thompson, Ella R., Gorringe, Kylie L., James, Paul A., Campbell, Ian G., Rowley, Simone M., McInerny, Simone, Devereux, Lisa, Goode, David, LifePool Investigators,, Wong-Brown, Michelle W., Scott, Rodney J., Trainer, Alison H.

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

- Regan, Meredith M., Pagani, Olivia, Villani, Laura, Pizzolitto, Stefano, Öhlschlegel, Christian, Sessa, Fausto, Peg Cámara, Vicente, Rodríguez Peralto, José Luis, MacGrogan, Gaëtan, Colleoni, Marco, Goldhirsch, Aron, Price, Karen N., Francis, Prudence A., Coates, Alan S., Gelber, Richard D., Viale, Giuseppe, Fleming, Gini F., Walley, Barbara A., Kammler, Roswitha, Dell'Orto, Patrizia, Russo, Leila, Szőke, János, Doimi, Franco

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

- Wong-Brown, Michelle W., Meldrum, Cliff J., Carpenter, Jane E., Clarke, Christine L., Narod, Steven A., Jakubowska, Anna, Rudnicka, Helena, Lubinski, Jan, Scott, Rodney J.

Symptoms of endocrine treatment and outcome in the BIG 1-98 study

- Huober, J., Cole, B. F., Smith, I., Wardley, A., Price, K. N., Goldhirsch, A., Coates, A. S., Colleoni, M., Gelber, R. D., Thürlimann, B., Rabaglio, M., Giobbie-Hurder, A., Wu, J., Ejlertsen, B., Bonnefoi, H., Forbes, J. F., Neven, P., Láng, I.

Immunohistochemical BAG1 expression improves the estimation of residual risk by IHC4 in postmenopausal patients treated with anastrazole or tamoxifen: a TransATAC study

- Afentakis, Maria, Dowsett, Mitch, Sestak, Ivana, Salter, Janine, Howell, Tony, Buzdar, Aman, Forbes, John, Cuzick, Jack

The impact of breast cosmetic and functional outcomes on quality of life: long-term results from the St. George and Wollongong randomized breast boost trial

- Hau, Eric, Browne, Lois, Capp, Anne, Delaney, Geoff P., Fox, Christopher, Kearsley, John H., Millar, Ewan, Nasser, Elias H., Papadatos, George, Graham, Peter H.

Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer

- Sestak, Ivana, Harvie, Michelle, Howell, Anthony, Forbes, John F., Dowsett, Mitch, Cuzick, Jack

BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer

- Wong, Michelle W., Nordfors, Cecilia, Mossman, David, Pecenpetelovska, Gordana, Avery-Kiejda, Kelly A., Talseth-Palmer, Bente, Bowden, Nikola A., Scott, Rodney J.

BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms

- Jakubowska, Anna, Gronwald, Jacek, Eils, Roland, Lubińki, Jan, Scott, Rodney J., Hamann, Ute, Menkiszak, Janusz, Górski, Bohdan, Huzarski, Tomasz, Byrski, Tomasz, Toloczko-Grabarek, Aleksandra, Gilbert, Michael, Edler, Lutz, Zapatka, Marc

Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology

- Lubiński, Jan, Korzeń, Marcin, Huzarski, Tomasz, Byrski, Tomasz, Gronwald, Jacek, Masojć, Bartłomiej, Lener, Marcin, Szymańska, Anna, Szymańska-Pasternak, Jolanta, Serrano-Fernàndez, Pablo, Piegat, Andrzej, Uciński, Rafał, Górski, Bohdan, Scott, Rodney, Cybulski, Cezary, Dębniak, Tadeusz, Jakubowska, Anna, Jaworska, Katarzyna, Wokołorczyk, Dominika, Mędrek, Krzysztof, Matyjasik, Joanna

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

- Pagani, Olivia, Gelber, Shari, Thürlimann, Beat, Fey, Martin F., Murray, Elizabeth, Forbes, John F., Coates, Alan S., Goldhirsch, Aron, Simoncini, Edda, Castiglione-Gertsch, Monica, Price, Karen N., Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Collins, John, Lindtner, Jurij

Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-Year update of International Breast Cancer Study Group Trial 11-93

- Thürlimann, Beat, Price, Karen N., Goldhirsch, Aron, Gelber, Richard D., Holmberg, Stig B., Crivellari, Diana, Colleoni, Marco, Collins, John, Forbes, John F., Castiglione-Gertsch, Monica, Coates, Alan S.